List view / Grid view
21 April 2017 | By Ingenza
Edinburgh-based Ingenza is celebrating after being named the Innovator of the Year at the 2017 Made in Scotland awards, held at the Glasgow Science Centre on the 19th of April...
21 April 2017 | By METTLER TOLEDO
METTLER TOLEDO’s Rainin TerraRack™ pipette tip racks are proving advantageous for the University of Glasgow’s Centre for Cell Engineering, where scientists are investigating cell differentiation and behavior on a variety of materials...
21 April 2017 | By Niamh Marriott, Junior Editor
Taking cannabidiol may cut seizures in half for some children and adults with Lennox-Gastaut syndrome (LGS), a severe form of epilepsy...
20 April 2017 | By Niamh Marriott, Junior Editor
Targovax has recruited the first patient in an exploratory Phase Ib clinical trial of TG02 in patients with locally recurrent RAS-mutated rectal cancer...
20 April 2017 | By Niamh Marriott, Junior Editor
Novartis demonstrated that 58% of patients with treatment-naïve severe aplastic anemia (SAA) achieved complete response at six months when treated...
20 April 2017 | By Wickham Laboratories
Wickham Laboratories Ltd will exhibit on Stand 309 at the Making Pharmaceuticals Conference on the 25th – 26th April 2017 at Ricoh Arena, Coventry...
20 April 2017 | By Aesica Pharmaceuticals
Product life cycle services expanded, including for high potent and controlled drugs...
20 April 2017 | By Niamh Marriott, Junior Editor
Novartis has entered into a clinical trial agreement with Allergan to conduct a Phase IIb study, involving the combination of a Novartis’ FXR agonist...
19 April 2017 | By Niamh Marriott, Junior Editor
GeNeuro have started a Phase 2a clinical study in Australia with GNbAC1 in patients with Type 1 diabetes. GNbAC1 is a monoclonal antibody designed to...
19 April 2017 | By Munters
Munters, global leaders in energy efficient air treatment, is delighted to be exhibiting on Stand 106 at Making Pharmaceuticals...
19 April 2017 | By Niamh Marriott, Junior Editor
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Novartis’ CTL019, an investigational chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of adult patients with relapsed and refractory (r/r) diffuse large B-cell lymphoma (DLBCL), who have failed two or more prior therapies. This is…
19 April 2017 | By Niamh Marriott, Junior Editor
The US Food and Drug Administration (FDA) has granted Enzyvant’s RVT-802, an investigational tissue-based therapy for the treatment of complete DiGeorge Syndrome (cDGS), breakthrough therapy designation as well as regenerative medicine advanced therapy (RMAT) designation. Both designations confer special access to the Office of Tissues and Advanced Therapies for development…
19 April 2017 | By Precision Polymer Engineering
Precision Polymer Engineering will be at Stand 303 at Making Pharmaceuticals (25-26 April, Coventry, UK), offering the benefits of our experience in pharmaceutical sealing to solve problems for critical process applications...
18 April 2017 | By Niamh Marriott, Junior Editor
Rigel Pharmaceuticals has submitted a new drug application to the US FDA for fostamatinib in patients with immune thrombocytopenia...
18 April 2017 | By Niamh Marriott, Junior Editor
Amarantus Bioscience has formed a wholly-owned subsidiary named Elto Pharma for the purpose of creating investment vehicles focused exclusively on the further development of Eltoprazine, Amarantus' mid-stage central nervous system (CNS) symptomatic treatment for Adult Attention Deficit and Hyperactivity Disorder (Adult ADHD), Alzheimer's Aggression and Parkinson's disease Levodopa-induced Dyskinesia (PD-LID).
